These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10626092)

  • 1. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats.
    Wikell C; Apelqvist G; Carlsson B; Hjorth S; Bergqvist PB; Kugelberg FC; Ahlner J; Bengtsson F
    Clin Neuropharmacol; 1999; 22(6):327-36. PubMed ID: 10626092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.
    Apelqvist G; Wikell C; Carlsson B; Hjorth S; Bergqvist PB; Ahlner J; Bengtsson F
    Clin Neuropharmacol; 2000; 23(6):304-17. PubMed ID: 11575864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.
    Rochat B; Kosel M; Boss G; Testa B; Gillet M; Baumann P
    Biochem Pharmacol; 1998 Jul; 56(1):15-23. PubMed ID: 9698084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective single-dose kinetics of citalopram and its metabolites in rats.
    Kugelberg FC; Carlsson B; Ahlner J; Bengtsson F
    Chirality; 2003 Aug; 15(7):622-9. PubMed ID: 12840828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
    Kugelberg FC; Apelqvist G; Carlsson B; Ahlner J; Bengtsson F
    Br J Pharmacol; 2001 Apr; 132(8):1683-90. PubMed ID: 11309239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats.
    Kugelberg FC; Druid H; Carlsson B; Ahlner J; Bengtsson F
    J Anal Toxicol; 2004; 28(8):631-7. PubMed ID: 15538956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical procedures for the determination of the selective serotonin reuptake inhibitor antidepressant citalopram and its metabolites.
    Unceta N; Goicolea MA; Barrio RJ
    Biomed Chromatogr; 2011 Jan; 25(1-2):238-57. PubMed ID: 21058412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic consequences of a citalopram treatment discontinuation.
    Voirol P; Rubin C; Bryois C; Kosel M; Buclin T; Baumann P
    Ther Drug Monit; 1999 Jun; 21(3):263-6. PubMed ID: 10365634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency.
    Bergqvist PB; Wikell C; Hjorth S; Apelqvist G; Bengtsson F
    Clin Neuropharmacol; 1997 Dec; 20(6):511-22. PubMed ID: 9403225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-phase postmortem redistribution of the enantiomers of citalopram and its demethylated metabolites in rats.
    Kugelberg FC; Kingbäck M; Carlsson B; Druid H
    J Anal Toxicol; 2005; 29(4):223-8. PubMed ID: 15975250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantiomeric screening of racemic citalopram and metabolites in human urine by entangled polymer solution capillary electrophoresis: an innovatory robustness/ruggedness study.
    Berzas-Nevado JJ; Villaseñor-Llerena MJ; Guiberteau-Cabanillas C; Rodríguez-Robledo V
    Electrophoresis; 2006 Feb; 27(4):905-17. PubMed ID: 16470634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of action of antidepressants: new data from Escitalopram].
    Fabre V; Hamon M
    Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
    Reis M; Lundmark J; Bengtsson F
    Ther Drug Monit; 2003 Apr; 25(2):183-91. PubMed ID: 12657912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
    Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
    Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
    Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
    Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
    Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
    Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography.
    Kosel M; Eap CB; Amey M; Baumann P
    J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):234-8. PubMed ID: 9869386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.
    Rochat B; Baumann P; Audus KL
    Brain Res; 1999 Jun; 831(1-2):229-36. PubMed ID: 10412001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate].
    Muraki I
    Hokkaido Igaku Zasshi; 2001 Mar; 76(2):57-70. PubMed ID: 11344903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.